Jacobs Levy Equity Management Inc. Raises Holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)

Jacobs Levy Equity Management Inc. boosted its holdings in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) by 2,225.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 461,959 shares of the company’s stock after acquiring an additional 442,090 shares during the quarter. Jacobs Levy Equity Management Inc. owned about 1.07% of Kyverna Therapeutics worth $1,728,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Gilead Sciences Inc. acquired a new stake in Kyverna Therapeutics during the fourth quarter worth $15,432,000. Barclays PLC increased its stake in Kyverna Therapeutics by 21.5% during the third quarter. Barclays PLC now owns 70,167 shares of the company’s stock worth $343,000 after acquiring an additional 12,418 shares during the last quarter. Kera Capital Partners Inc. acquired a new stake in Kyverna Therapeutics during the fourth quarter worth $1,407,000. Rhumbline Advisers increased its stake in Kyverna Therapeutics by 31.1% during the fourth quarter. Rhumbline Advisers now owns 25,920 shares of the company’s stock worth $97,000 after acquiring an additional 6,153 shares during the last quarter. Finally, Norges Bank acquired a new stake in Kyverna Therapeutics during the fourth quarter worth $150,000. Institutional investors and hedge funds own 18.08% of the company’s stock.

Kyverna Therapeutics Trading Up 1.4%

KYTX opened at $2.18 on Friday. Kyverna Therapeutics, Inc. has a 12-month low of $1.78 and a 12-month high of $17.06. The firm has a market cap of $94.22 million, a price-to-earnings ratio of -0.63 and a beta of 2.17. The stock’s 50-day moving average price is $2.15 and its 200 day moving average price is $3.30.

Kyverna Therapeutics (NASDAQ:KYTX) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($1.03) earnings per share for the quarter, topping the consensus estimate of ($1.21) by $0.18. On average, research analysts forecast that Kyverna Therapeutics, Inc. will post -3.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

KYTX has been the topic of several research analyst reports. Morgan Stanley cut their price objective on Kyverna Therapeutics from $40.00 to $20.00 and set an “overweight” rating on the stock in a report on Tuesday, April 1st. HC Wainwright decreased their target price on Kyverna Therapeutics from $6.00 to $4.00 and set a “neutral” rating on the stock in a research note on Thursday, April 3rd. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Kyverna Therapeutics presently has an average rating of “Buy” and an average target price of $18.33.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.